ATE523484T1 - Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure - Google Patents

Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure

Info

Publication number
ATE523484T1
ATE523484T1 AT06759590T AT06759590T ATE523484T1 AT E523484 T1 ATE523484 T1 AT E523484T1 AT 06759590 T AT06759590 T AT 06759590T AT 06759590 T AT06759590 T AT 06759590T AT E523484 T1 ATE523484 T1 AT E523484T1
Authority
AT
Austria
Prior art keywords
carbamoylmethyl
methyl
optical solution
cmh
hexanic acid
Prior art date
Application number
AT06759590T
Other languages
English (en)
Inventor
Lilach Hedvati
Noor Ziv Dee
Claude Singer
Gideon Pilarski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE523484T1 publication Critical patent/ATE523484T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/20—Preparation of optical isomers by separation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06759590T 2005-05-10 2006-05-10 Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure ATE523484T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67978405P 2005-05-10 2005-05-10
US68969905P 2005-06-09 2005-06-09
US73300905P 2005-11-02 2005-11-02
US73563405P 2005-11-09 2005-11-09
US74095005P 2005-11-29 2005-11-29
PCT/US2006/018273 WO2006122259A1 (en) 2005-05-10 2006-05-10 Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid

Publications (1)

Publication Number Publication Date
ATE523484T1 true ATE523484T1 (de) 2011-09-15

Family

ID=36940669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759590T ATE523484T1 (de) 2005-05-10 2006-05-10 Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure

Country Status (9)

Country Link
US (4) US20070043241A1 (de)
EP (1) EP1879854B1 (de)
KR (2) KR20070118305A (de)
AT (1) ATE523484T1 (de)
CA (1) CA2604624A1 (de)
ES (1) ES2372700T3 (de)
IL (1) IL185032A0 (de)
MX (1) MX2007014129A (de)
WO (1) WO2006122259A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004643A2 (en) * 2007-05-08 2009-01-08 Cadila Healthcare Limited An improved process for preparation of (s)-pregabalin and intermediates thereof
WO2009125427A2 (en) * 2008-02-18 2009-10-15 Matrix Laboratories Limited Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid
UA103997C2 (ru) 2008-05-21 2013-12-25 Сандоз Аг Способ стереоселективного ферментативного гидролиза эстера 5-метил-3-нитрометилгексановой кислоты
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CN113801031B (zh) * 2021-10-26 2023-12-26 浙江华海药业股份有限公司 一种普瑞巴林的纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE86971T1 (de) * 1986-08-13 1993-04-15 Ciba Geigy Ag Verfahren zur herstellung von 5-amino-4hydroxyvalerians|ure-derivaten.
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
DE19530637A1 (de) * 1995-08-21 1997-02-27 Bayer Ag Verfahren zur Herstellung von 2,2-Difluorbenzo[1.3]dioxolcarbaldehyden
CN1094757C (zh) * 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
ES2130079B1 (es) * 1997-07-10 2000-01-16 Esteve Labor Dr Resolucion de aminas
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
AU777046B2 (en) * 2000-01-27 2004-09-30 Warner-Lambert Company Llc Asymmetric synthesis of pregabalin
EP1268368A2 (de) * 2000-04-04 2003-01-02 Brandeis University Katalytische asymmetrische desymmetrisierung von mesoverbindungen
US6833458B2 (en) * 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
AU2002333374B2 (en) * 2001-09-03 2007-03-22 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
DE10203122A1 (de) * 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
US20030225149A1 (en) * 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US6942377B1 (en) * 2003-02-19 2005-09-13 Robert B Goldstein Thermoreactive beverage stirrer
RU2335342C2 (ru) * 2004-03-12 2008-10-10 Уорнер-Ламберт Компани Ллс C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина
ATE405572T1 (de) * 2004-04-01 2008-09-15 Warner Lambert Co Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese
UA82292C2 (uk) 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
ME01067B (me) * 2004-06-21 2012-10-20 Warner Lambert Co Dobijanje pregabalina i srodnih jedinjenja
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CN1634869A (zh) 2004-12-06 2005-07-06 北京阜康仁生物制药科技有限公司 普瑞巴林新晶型及其制备方法
CN101300224A (zh) 2005-04-11 2008-11-05 特瓦制药工业有限公司 制备(s)-普瑞巴林的方法
WO2006122258A1 (en) 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
BRPI0605833A (pt) 2005-05-10 2007-12-18 Teva Pharma pregabalina livre de ácido isobutilglutárico e um processo para sua preparação
EP1879852A1 (de) 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Lactamfreies pregabalin und herstellungsverfahren dafür
US20060270871A1 (en) * 2005-05-30 2006-11-30 Khanduri Chandra H Polymorphic form i of pregabalin and processes for its preparation
CN100410242C (zh) 2005-06-23 2008-08-13 江苏恩华药业股份有限公司 普瑞巴林中间体及其制备方法
CZ297970B6 (cs) 2005-08-10 2007-05-09 Zentiva, A. S Zpusob výroby (S)-3-(aminomethyl)-5-methyl-hexanové kyseliny (pregabalinu)
WO2007035789A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
ITMI20061297A1 (it) 2006-07-04 2008-01-05 Laboratorio Chimico Int Spa Procedimento per la preparazione della'acido (r)-(-)-3-(carbamoilmetil)-5-metilesanoico e del pregabalin e intermedi di sintesi
AU2007274034B2 (en) 2006-07-12 2012-11-15 Generics [Uk] Limited Process of preparing a gamma-amino acid
GB0614133D0 (en) 2006-07-15 2006-08-23 Pliva Istrazivanje I Razvoj D Process for preparing a pharmaceutical compound
US20080014280A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous pregabalin and process for the preparation thereof
WO2008062460A2 (en) 2006-10-06 2008-05-29 Cadila Healthcare Limited Crystalline forms of pregabalin
GB0619888D0 (en) 2006-10-07 2006-11-15 Pliva Istrazivanje I Razvoj D New polymorphic forms of pregabalin
EP1992609A1 (de) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. Verfahren für die Herstellung einer (S)(+)-3-(Aminomethyl)-5-Methylhexan-Säure
EP2017273A1 (de) 2007-07-18 2009-01-21 Laboratorios del Dr. Esteve S.A. Verfahren zur enantioselektiven Herstellung von Pregabalin
ITMI20072262A1 (it) 2007-12-03 2009-06-04 Dipharma Francis Srl Procedimento per la preparazione di acido (s)(+)-3-(amminometil)-5-metilesanoico

Also Published As

Publication number Publication date
EP1879854B1 (de) 2011-09-07
WO2006122259A1 (en) 2006-11-16
US7619112B2 (en) 2009-11-17
IL185032A0 (en) 2007-12-03
US20070043241A1 (en) 2007-02-22
ES2372700T3 (es) 2012-01-25
KR20090019016A (ko) 2009-02-24
MX2007014129A (es) 2008-01-11
US7678938B2 (en) 2010-03-16
EP1879854A1 (de) 2008-01-23
KR20070118305A (ko) 2007-12-14
US20070287748A1 (en) 2007-12-13
US20070287860A1 (en) 2007-12-13
CA2604624A1 (en) 2006-11-16
US20070287859A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
EA200870262A1 (ru) Способ получения оптических активных хиральных аминов
BRPI0921408A2 (pt) processo para a fabricação de (r)-2-acetamido-n-benzil-3-metoxipropion-amida (i) opticamente pura.
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BRPI0413973A (pt) compostos
DK2057136T3 (da) Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser
CL2009002201A1 (es) Procedimiento de sintesis de ivabradina por aminacion reductiva y posterior resolucion optica; y uno de los compuestos intermediarios considerados.
WO2007011951A3 (en) Purification of paricalcitol
ATE402753T1 (de) Reinigung von ionischen flüssigkeiten
AR060091A1 (es) Procedimiento para preparar lentes oftalmicas
DK2082054T3 (da) Fremgangsmåde til forbedring af udbyttet af celluloseomdannelsesprocesser
ATE523484T1 (de) Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure
UA94449C2 (ru) Способ получения оптически активного соединения оксида хромена
HK1138290A1 (en) Method of purification of hydrophobic proteins
DE602005022099D1 (de) Fluorisierungsverfahren zur synthese von 2-ä18fü fluoro-2-deoxy-d-glukose
EA200801297A1 (ru) Способ снижения уровня постпрандиальной глюкозы
NO20085359L (no) Fremgangsmate for fremstilling av renset hydrokinon
WO2008055110A3 (en) Photonic crystal euv photoresists
DK1838670T3 (da) Fremgangsmåde til fremstilling af carvedilol og dets enantiomere
DK1907396T3 (da) Fremgangsmåde til fremstilling af 4-beta-amino-4'-demethyl-4-deoxypodophyllotoxin
ATE442371T1 (de) Víllig lísungsmittelfreie cefotetan säure und verfahren zu ihrer herstellung.
GT200400195A (es) Nuevo proceso para reducir el nivel de impurezas en una muestra de mesotriona
WO2010058409A3 (en) Optical purification of esomeprazole
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
DE602006003204D1 (de) Reinigungsverfahren von Moxonidine
DK1885707T3 (da) Fremgangsmåde til oprensning af 10-deacetylbaccatin III fra 10-deacetyl-2-debenzoyl-2-pentenoylbaccatin III

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties